Drugs /

vgx-3100

Back to Drugs List
Associated Genetic Biomarkers

Overview

Clinical Trials

View Clinical Trials for vgx-3100

Vgx-3100 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating vgx-3100, 1 is phase 2 (1 open) and 1 is phase 3 (0 open).

CDKN2A Overexpression and HPV Positive are the most frequent biomarker inclusion criteria for vgx-3100 clinical trials.

High grade cervical intraepithelial neoplasia and vulvar neoplasm are the most common diseases being investigated in vgx-3100 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Vgx-3100
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Vgx-3100
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating vgx-3100 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Categories [2]:
Immunotherapies

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.